Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,539 JPY | +0.59% | +1.48% | +33.28% |
04-12 | Daito Pharmaceutical Co.,Ltd. announces an Equity Buyback for 350,000 shares, representing 2.23% for ¥1,000 million. | CI |
04-12 | Daito Pharmaceutical Co.,Ltd. authorizes a Buyback Plan. | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- With a P/E ratio at 11.96 for the current year and 10.17 for next year, earnings multiples are highly attractive compared with competitors.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company appears to be poorly valued given its net asset value.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+33.28% | 251M | - | ||
+19.62% | 43.27B | B- | ||
+24.52% | 22.92B | B+ | ||
+20.29% | 15.43B | - | ||
+7.48% | 12.95B | B+ | ||
+42.51% | 11.83B | B | ||
-8.84% | 6.91B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+13.13% | 5.55B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4577 Stock
- Ratings Daito Pharmaceutical Co.,Ltd.